New Snoring After Starting Testosterone Therapy and What It Can Signal About Your Airway
What the testosterone therapy snoring sleep apnea evidence shows and what to tell your prescriber
New snoring in your first months on testosterone has a documented time course, a European evidence position that differs from the American one, and a short list of checks worth doing before your next dose.
The short answer on testosterone therapy snoring sleep apnea
New snoring after starting testosterone is worth reporting to your prescriber, and it is rarely a reason to stop treatment on your own. Note when it began, and ask for a haematocrit check and a sleep assessment. The evidence behind testosterone therapy snoring sleep apnea is narrower and more time-limited than most pages suggest. In a randomised placebo-controlled trial of 67 men with obesity and severe obstructive sleep apnoea, testosterone worsened the oxygen desaturation index (ODI) by 10.3 events per hour at week 7 and increased time with SpO2 below 90% by 6.1% against placebo. By week 18, neither difference remained significant (Hoyos et al., Clinical Endocrinology, 2012).
Snoring is a symptom, not a diagnosis. It can be the first audible sign of sleep-disordered breathing, the European umbrella term covering primary snoring, obstructive sleep apnoea syndrome (OSAS) and central sleep apnoea. Before your appointment, work through the ten warning signs that justify a referral, because what you report is what gets tested.
- The first two months after starting or raising a dose is where the published signal appeared.
- Snoring alone is not apnoea; witnessed pauses, gasping and daytime sleepiness change the picture.
What most guides on testosterone and snoring get wrong
The first flaw is geography. Most testosterone therapy snoring sleep apnea advice online quotes only the American position and never mentions the European one. The two do not agree. A European reader then arrives at their andrology clinic expecting a conversation their clinician is not going to have.
The second is time. Almost nobody says when the effect appears or whether it lasts. That fact is what stops people abandoning treatment in a panic. The trial signal peaked around week 7 and had faded by week 18.
A third gap is who gets written about. Mainstream pages assume a middle-aged cisgender man on replacement therapy for hypogonadism, and almost none cover masculinising hormone therapy, where the largest published signal sits. Searches for ronflement et apnée du sommeil sous testostérone, Testosteron Schnarchen Schlafapnoe or testosterona ronquidos apnea del sueño return the opposite topic: untreated apnoea lowering testosterone, not therapy linked to new snoring.
- Check which guideline your prescriber follows before assuming what they will say.
- The published effect was transient, and the group with the biggest signal is the one nobody writes for.
How testosterone therapy snoring sleep apnea changes are thought to happen
Exogenous testosterone is thought to affect night-time breathing through four routes at once, and they are not equally well supported.
Ventilatory control and chemoreflex sensitivity
The mechanism most often proposed. Testosterone appears to alter hypoxic and hypercapnic chemoreflex sensitivity, the system deciding how hard you breathe as carbon dioxide rises. Push it towards overshoot and breathing becomes unstable, described as high loop gain. The effect is clearest during REM-related respiratory depression.
Upper airway anatomy and dilator muscle tone
Testosterone changes body composition, including fat distribution around the neck, and may influence genioglossus and upper airway dilator muscle tone. A more collapsible throat narrows further when you lie flat. Pharyngeal collapsibility turns quiet airflow into vibration, and vibration is snoring.
Rostral fluid shift and sodium retention
Androgens promote sodium and water retention. Fluid pooled in the legs by day moves upward once you lie down, adding tissue volume around the neck. Small change, loud result.
Erythrocytosis and blood thickness
Testosterone raises red cell mass. Erythrocytosis, also called secondary polycythaemia, thickens the blood, which is thought to matter during the brief oxygen dips that punctuate disturbed breathing. This is the thread tying your blood test to your snoring.
- Part of the proposed mechanism is anatomical, part is about breathing control, and they need different fixes.
- Your haematocrit result belongs in the same conversation as your snoring.
Europe and the United States formally disagree about this
European testosterone therapy snoring sleep apnea guidance does not match the American version. The European Association of Urology Guidelines on Sexual and Reproductive Health (2026), section 3.5.7, state at level of evidence 1b that there is no evidence of a relationship between testosterone therapy and mild, moderate or CPAP-treated severe sleep apnoea. The US Endocrine Society clinical practice guideline (Bhasin et al., 2018) recommends against starting testosterone therapy in people with untreated severe obstructive sleep apnea.
Both read the same trial. The EAU treats the Hoyos result as a transient signal resolved by week 18, and notes that combined CPAP plus transdermal testosterone gel was more effective than CPAP alone. That is close to the opposite of the American caution.
Your own product leaflet adds a more precise figure. The summary of product characteristics (SmPC) for testosterone undecanoate 1000 mg/4 ml depot injection, sold in Europe as Nebido and as generics, was revised on 15 December 2025. It lists sleep apnoea as an uncommon adverse reaction, at least 1 in 1,000 and fewer than 1 in 100 users, and section 4.4 states that pre-existing sleep apnoea may be potentiated.
| Question | EAU Guidelines, Europe (2026) | Endocrine Society, US (2018) | EU testosterone SmPC (2025) |
|---|---|---|---|
| Does testosterone worsen apnoea | No evidence of a relationship, LE 1b | Treated as a real risk in severe disease | Listed as an uncommon adverse reaction |
| Starting with untreated severe apnoea | Not listed as a barrier | Recommends against starting | Pre-existing apnoea may be potentiated |
| Haematocrit action point | 48-50% needs careful evaluation, above 54% needs action | Elevated haematocrit is a reason not to start | Regular haemoglobin and haematocrit monitoring |
- A European clinician may reasonably be less alarmed than an American article predicts.
- The frequency printed in your own EU leaflet is uncommon, not typical.
New snoring on masculinising hormone therapy
If you are transmasculine or non-binary and started snoring after beginning gender-affirming hormone therapy (GAHT), the association is documented and you are not imagining it. A propensity-score-matched population cohort of 22,745 transmasculine individuals on testosterone found obstructive sleep apnoea risk 3.25 times higher than in cisgender females (95% CI 2.88-3.67) and 1.74 times higher than in cisgender males (Christ et al., International Journal of Transgender Health, 2025).
The more revealing number is the other one. Central sleep apnoea risk was 7.34 times higher than in cisgender females (95% CI 2.52-21.41). Central events are not blockages. They are pauses where the signal to breathe briefly stops arriving, which fits the chemoreflex mechanism better than the anatomy one. That is the clearest published hint that the testosterone therapy snoring sleep apnea picture is partly about ventilatory control, not only airway shape.
Read these as population-level hazards, not personal odds, and note how wide the confidence interval on the central figure is. None of this is a reason to stop masculinising hormone therapy. It is a reason to raise snoring at your next review.
- The transmasculine signal is larger for central than obstructive events, which changes what will help.
- Ask for the standard monitoring, not for your hormones to be paused.
Telling an airway problem from a breathing-drive problem
Snoring always comes from the airway. What disturbs your sleep may not. Obstructive events are blockages, where the throat closes while effort continues. Central events are silences, where effort itself pauses. That distinction decides which treatments can help.
| Clue | More typical of an airway pattern | More typical of a control pattern |
|---|---|---|
| Sound | Loud snoring with gasping or choking arousals | Quiet pauses with little snoring |
| Position | Worse on the back, better on the side | Less consistently position-linked |
| Nose | Blocked nose, mouth breathing and high nasal resistance worsen it | Nasal resistance is less relevant |
| On testing | Raised apnoea-hypopnoea index with continued respiratory effort | Pauses recorded without respiratory effort |
| What can help | Positional therapy, nasal devices, mandibular advancement device, CPAP | Dose or route review, specialist ventilation assessment |
You cannot separate them at home. These clues shape the question you ask, not the answer.
- Airway devices act on obstruction and cannot correct a drive-related pattern.
- Only a recorded study distinguishes the two reliably.
What actually happens at your next dose review
The dose review is where this gets addressed or missed. The EAU Guidelines (2026) set monitoring at 3, 6 and 12 months, then annually. Two readings get checked, and both connect to snoring: your haematocrit and your trough testosterone level, taken just before the next dose is due.
| Haematocrit result | What the EAU Guidelines (2026) indicate |
|---|---|
| 48-50% at baseline | Careful evaluation before starting, particularly with OSAS or COPD |
| Above 54% | Adjust or withdraw therapy, with venesection or therapeutic phlebotomy if required |
Erythrocytosis does not merely share a clinic visit with your snoring. Among 474 men on testosterone replacement therapy (TRT), 13.1% developed polycythaemia, and obstructive sleep apnoea was independently associated with it at an odds ratio of 2.09 (Lundy et al., Journal of Sexual Medicine, 2020). Of the men with both, 59.5% were managed with a dose reduction and 37.8% with phlebotomy.
Route matters as well. A systematic review found erythrocytosis rates of up to 66.7% in cisgender and transgender men on prescription testosterone, with intramuscular formulations and higher doses carrying more risk (Blood Advances, 2025). The European standard is a 1000 mg depot lasting roughly 10 to 12 weeks, a very different peak-to-trough curve from a daily gel or a shorter-acting testosterone enantate injection. If your snoring clusters in the days after an injection, say so. Dose titration or a route change is a far smaller intervention than stopping.
- Ask for your actual haematocrit number and the date of your last trough level.
- Snoring that tracks your injection cycle is useful evidence for a titration decision.
What a testosterone therapy snoring sleep apnea assessment involves
Assessment starts with questions, not machines. Clinicians commonly use the Epworth Sleepiness Scale to grade excessive daytime sleepiness and the STOP-BANG questionnaire to estimate risk, and they measure neck circumference, with around 40 cm often treated as a flag. In the UK and much of Europe this is a GP-gatekept pathway.
Testing then escalates in two steps. Most European services start with respiratory polygraphy or a home sleep apnoea test (HSAT), a limited-channel recording of airflow, effort and oxygen saturation, and reserve full polysomnography for unclear results or a suspected central pattern. This comparison of a home study against a full laboratory night sets out what each measures.
Keep perspective on the numbers. Moderate-to-severe sleep-disordered breathing was found in 49.7% of men and 23.4% of women in the Swiss HypnoLaus study of 2,121 people (Heinzer et al., The Lancet Respiratory Medicine, 2015). Plenty of people snore. Not all of them have apnoea, and not every case involves a hormone.
One consequence Europeans should know before reporting the symptom. Commission Directive 2014/85/EU is binding across EU member states. It defines moderate OSAS as an apnoea-hypopnoea index (AHI) of 15 to 29 and severe OSAS as 30 or more, both with excessive daytime sleepiness, and requires authorised medical assessment before a licence is issued or renewed. Diagnosed drivers face review at intervals of no more than three years for Group 1 and one year for Group 2. Control of the condition is the point, not disqualification.
- A home limited-channel study is usually the first test, not a full laboratory night.
- An OSAS diagnosis in the EU carries a licence review requirement, so plan for it rather than avoid testing.
A two-week log and the words to use at your appointment
Vague reports get vague answers. Ten focused minutes with a prescriber beat a month of worrying.
- Date the change. Note when the snoring began, and how many weeks after your first dose or dose increase.
- Record two nights. A phone recording app shows whether the snoring runs continuously or is broken by silences and gasps.
- Ask whoever sleeps near you. Have they heard you stop breathing, gasp, or choke awake.
- Score yourself. Complete the Epworth Sleepiness Scale and the STOP-BANG questionnaire, and bring both totals.
- Find your last bloods. Note your haematocrit and the date of your last trough testosterone level.
Open with something close to this: "I started snoring [number] weeks after my [first injection, dose increase or switch to gel]. My partner has heard me stop breathing [number] times. My Epworth score is [score]. Can we check my haematocrit and trough testosterone, and can you refer me for a sleep study?"
1Is my dose or my route the likely driver
Ask whether the timing of the snoring matches your peak levels, and whether a different formulation would flatten that curve.
2What changes if it turns out to be central
A central pattern moves the plan away from airway devices, towards dose review and specialist assessment.
- Bring dates, recordings, two questionnaire scores and your last blood results.
- Named questions get named answers, which is what a short appointment needs.
What can help the snoring while you wait for answers
The honest sequence first. New snoring on testosterone is a reason to get assessed, not a reason to buy a device. Book the assessment. European waiting lists are long though, and a partner losing sleep for months deserves an answer in the meantime.
The lowest-downside measures come first. Sleep on your side rather than your back, avoid alcohol before bed, and treat a blocked nose, because high nasal resistance and mouth breathing amplify snoring. Where weight has shifted around the neck, clinicians commonly raise gradual weight reduction. The NHS lists nasal dilators, strips, decongestants and sprays among recognised snoring treatments, alongside mandibular advancement devices and chin straps.
If assessment has excluded apnoea or shown it to be mild-to-moderate, the nasal component is where a device fits. Back2Sleep is a CE-certified Class I soft silicone intranasal stent that keeps the nasal airway open during sleep, with a starter kit of four sizes at around €39, no prescription, no electricity and no tubing. Two limits need stating plainly. It is not a CPAP replacement for severe obstructive sleep apnoea. And because testosterone is thought to act partly on ventilatory control rather than purely on airway anatomy, a nasal stent cannot address a central or drive-related component. Using one while you wait does not replace attending the sleep study.
- Position, alcohol timing and nasal patency are the free interventions worth trying first.
- A nasal device addresses obstruction only, and never substitutes for the assessment you have been referred for.
What Back2Sleep Users Say
Frequently Asked Questions
How long after starting testosterone does snoring usually begin?
The trial evidence points to the first two months as the expected window. Testosterone worsened the oxygen desaturation index by 10.3 events per hour at week seven, and that difference had gone by week 18 (Hoyos et al., Clinical Endocrinology, 2012). Log the date it started, then report it at your next review.
I started snoring after my testosterone injection, should I stop my treatment?
No, not on your own. Stopping or skipping doses without medical advice can destabilise your treatment and your wellbeing. Report the snoring to whoever prescribes your testosterone and ask for a haematocrit check, a trough testosterone level and a sleep assessment. Dose, timing or route can often be adjusted instead of stopped.
Can you take testosterone if you already have sleep apnoea?
European and American guidance differ. The EAU Guidelines on Sexual and Reproductive Health (2026) state there is no evidence of a relationship between testosterone therapy and mild, moderate or CPAP-treated severe sleep apnoea. The US Endocrine Society (2018) recommends against starting testosterone in untreated severe obstructive sleep apnea. Treated apnoea changes the conversation.
Do trans men on testosterone get sleep apnoea more often?
A 2025 propensity-matched cohort of 22,745 transmasculine people on testosterone found obstructive sleep apnoea risk 3.25 times higher than in cisgender women and 1.74 times higher than in cisgender men (International Journal of Transgender Health, 2025). That is a population-level hazard, not your personal odds. It is a screening prompt, never a reason to stop hormone therapy.
Does testosterone gel cause less snoring than testosterone injections?
No head-to-head trial answers this for snoring. What is known is that route matters for a related risk: erythrocytosis rates of up to 66.7% were found in people on prescription testosterone, with intramuscular formulations and higher doses carrying more risk (Blood Advances, 2025). Switching from a depot injection to a daily gel changes your peak-to-trough profile, so raise it.
Is a home sleep apnoea test enough to check snoring on testosterone?
Usually yes, as a first step. Most European services start with respiratory polygraphy or a home limited-channel study, then move to full polysomnography if results are unclear or a central pattern is suspected. Ask which one you are being booked for, because a home test measures breathing and oxygen but not sleep stages.
Do I need a sleep study before my doctor will keep prescribing testosterone?
The EAU Guidelines (2026) set monitoring at 3, 6 and 12 months then annually, focused on haematocrit and trough testosterone rather than routine sleep studies. If you report loud snoring with witnessed pauses, gasping or daytime sleepiness, a referral for testing becomes reasonable, and in the UK that goes through your GP.
Do I have to tell my driving licence authority about snoring on testosterone?
Snoring alone, no. A diagnosis changes that. Commission Directive 2014/85/EU is binding across EU member states: moderate OSAS with an apnoea-hypopnoea index of 15 to 29, or severe at 30 or more, with excessive daytime sleepiness, requires authorised medical assessment. Licence review follows at most every three years for ordinary drivers.
Ready for quieter nights? Discover the Back2Sleep starter kit and find the right fit for you.
Not sure if you are at risk? Take our sleep risk screening to find out in just a few minutes.
Want to learn how it works? Explore the Back2Sleep nasal stent designed for comfortable, effective relief.